Home The Word Brain	My Amedeo FAQ Privacy About
	C49 + CC Journal Club For more information, please refer to our special emails from April 13 and May 19.

Inflammatory Bowel Diseases

Free Subscription Articles published in Am J Gastroenterol Retrieve available abstracts of 158 articles: HTML format

Single Articles

May 2025
1. CHESTER MA, Keefer L
   Beyond Depression and Anxiety in Inflammatory Bowel Diseases: Forging a Path Toward Emotional Healing.
   Am J Gastroenterol. 2025;120:999-1006.
   PubMed     Abstract available
   
   
   
2. ADLER J, Galanko JA, Ammoury R, Benkov KJ, et al
   HLA DQA1*05 and Risk of Antitumor Necrosis Factor Treatment Failure and Anti-Drug Antibody Development in Children With Crohn's Disease.
   Am J Gastroenterol. 2025;120:1076-1086.
   PubMed     Abstract available
   
   
   April 2025
3. KOCHHAR GS, Dziegielewski C, Schairer JN, Cross RK, et al
   Role of Endoscopy in Inflammatory Bowel Disease: What Every Gastroenterologist Should Know.
   Am J Gastroenterol. 2025 Apr 29. doi: 10.14309/ajg.0000000000003507.
   PubMed     Abstract available
   
   
   
4. OHNO M, Nishida A, Yokota Y, Imai T, et al
   Early Stage Crohn's Disease-Associated Small Bowel Adenocarcinoma at Ileal Stenosis Detected by Ballon-Assisted Enteroscopy.
   Am J Gastroenterol. 2025 Apr 10. doi: 10.14309/ajg.0000000000003484.
   PubMed    
   
   
   
5. MELMED GY, Oliver B, Kennedy A, Hou JK, et al
   LONG-TERM SUSTAINED IMPROVEMENT IN UNPLANNED HEALTHCARE UTILIZATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE.
   Am J Gastroenterol. 2025 Apr 7. doi: 10.14309/ajg.0000000000003454.
   PubMed     Abstract available
   
   
   
6. SEGURA A, Brensinger C, Pate V, Siddique SM, et al
   Association of Race and Ethnicity with Healthcare Utilization for Inflammatory Bowel Disease in the United States: A Retrospective Cohort Study.
   Am J Gastroenterol. 2025 Apr 1. doi: 10.14309/ajg.0000000000003438.
   PubMed     Abstract available
   
   
   
7. DRITTEL D, Schreiber-Stainthorp W, Delau O, Gurunathan SV, et al
   Severe Polypharmacy Increases Risk of Hospitalization Among Older Adults With Inflammatory Bowel Disease.
   Am J Gastroenterol. 2025;120:844-855.
   PubMed     Abstract available
   
   
   March 2025
8. KAYAL M
   A Practical Guide to the Use of Guselkumab for Moderate-Severe Ulcerative Colitis.
   Am J Gastroenterol. 2025 Mar 31. doi: 10.14309/ajg.0000000000003446.
   PubMed    
   
   
   
9. DUNLEAVY K, Pedersen K, Cima R, Chedid V, et al
   Ileal pouch adenocarcinoma in a young patient with newly diagnosed Crohn's-like disease of the pouch.
   Am J Gastroenterol. 2025 Mar 26. doi: 10.14309/ajg.0000000000003426.
   PubMed    
   
   
   
10. CALDERA F, Hayney MS, Farraye FA, Fischer M, et al
    Low incidence of Varicella in Pediatric Patients with Inflammatory Bowel Disease.
    Am J Gastroenterol. 2025 Mar 18. doi: 10.14309/ajg.0000000000003418.
    PubMed     Abstract available
    
    
    
11. TORRES J, Panes J, Siegel CA, Dubinsky MC, et al
    Symptom Resolution and Meaningful Improvement in Quality of Life With Risankizumab in Patients With Ulcerative Colitis: Post Hoc Analysis of the Randomized INSPIRE and COMMAND Studies.
    Am J Gastroenterol. 2025 Mar 17. doi: 10.14309/ajg.0000000000003420.
    PubMed     Abstract available
    
    
    
12. LEE SD, Vermeire S, Ungaro R, Vadhariya A, et al
    Mirikizumab Improves Quality of Life and Work Productivity in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 study.
    Am J Gastroenterol. 2025 Mar 13. doi: 10.14309/ajg.0000000000003410.
    PubMed     Abstract available
    
    
    
13. LEE SD, Ehrlich AC, Pellanda P, Kaiser C, et al
    Long-Term Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis: An Integrated 2-Year Safety Analysis.
    Am J Gastroenterol. 2025 Mar 12. doi: 10.14309/ajg.0000000000003407.
    PubMed     Abstract available
    
    
    
14. DZIEGIELEWSKI C, Yuan Y, Ma C, Boland BS, et al
    IL-23p19 Antagonists vs. Ustekinumab for Treatment of Crohn's Disease: A Meta-analysis of Randomized Controlled Trials.
    Am J Gastroenterol. 2025 Mar 12. doi: 10.14309/ajg.0000000000003406.
    PubMed     Abstract available
    
    
    
15. YANG JC, Janssen EM, Wallace MJ, Sheahan A, et al
    Quantifying Patient Preferences for Risk Tolerance With Novel Dual Biologic Therapies for Inflammatory Bowel Disease.
    Am J Gastroenterol. 2025 Mar 6. doi: 10.14309/ajg.0000000000003397.
    PubMed     Abstract available
    
    
    
16. GOODWIN SW, Wilk P, Yuan Y, Haan M, et al
    Increasing rate of hospitalization for inflammatory bowel disease is an age-related effect: A Canadian Population Study.
    Am J Gastroenterol. 2025 Mar 4. doi: 10.14309/ajg.0000000000003385.
    PubMed     Abstract available
    
    
    February 2025
17. LO B, Moller B, Igel C, Wildt S, et al
    Improving the Real-time Classification of Disease Severity in Ulcerative Colitis: Artificial Intelligence as the Trigger for a Second Opinion.
    Am J Gastroenterol. 2025 Feb 28. doi: 10.14309/ajg.0000000000003382.
    PubMed     Abstract available
    
    
    
18. FU CJ, Chen HW, Wei JC
    Spine and Sacroiliac Joint Involvement in Newly Diagnosed Patients With Inflammatory Bowel Disease: Clinical and MRI Findings From a Population-Based Cohort.
    Am J Gastroenterol. 2025 Feb 25. doi: 10.14309/ajg.0000000000003340.
    PubMed    
    
    
    
19. NORGARD BM, Thorarinsson CT, Nielsen J, Dalal RS, et al
    Predictors for chronic opioid use in patients with inflammatory bowel disease - a population based cohort study.
    Am J Gastroenterol. 2025 Feb 5. doi: 10.14309/ajg.0000000000003353.
    PubMed     Abstract available
    
    
    
20. CALAFAT M, Suria C, Mesonero F, de Francisco R, et al
    HIV Infection Is Associated With a Less Aggressive Phenotype of Inflammatory Bowel Disease: A Multicenter Study of the ENEIDA Registry.
    Am J Gastroenterol. 2025;120:431-439.
    PubMed     Abstract available
    
    
    
21. SYSTROM HK, Rai V, Singh S, Baidoo L, et al
    When Perfect Is the Enemy of Good: Results of a RAND Appropriateness Panel on Treat to Target in Asymptomatic Inflammatory Bowel Disease.
    Am J Gastroenterol. 2025;120:420-430.
    PubMed     Abstract available
    
    
    January 2025
22. STEINSBO O, Aasprong OG, Aabakken L, Karlsen LN, et al
    Fecal Calprotectin Correlates with Disease Extent but Remains a Reliable Marker of Mucosal Healing in Ulcerative Colitis.
    Am J Gastroenterol. 2025 Jan 30. doi: 10.14309/ajg.0000000000003339.
    PubMed     Abstract available
    
    
    
23. OLIVERA PA, Parks ML, Zubiaurre I, Peyrin-Biroulet L, et al
    Comparative Improvement in Health-Related Quality of Life with Advanced Therapies for Moderate-to-Severe Crohn's Disease: A Network Meta-Analysis.
    Am J Gastroenterol. 2025 Jan 29. doi: 10.14309/ajg.0000000000003333.
    PubMed     Abstract available
    
    
    
24. MARILD K, Soderling J, Stephansson O, Axelrad J, et al
    Inflammatory Bowel Disease, Periconceptional Disease Activity, and Risk of Major Congenital Anomalies: A Nationwide Cohort Study.
    Am J Gastroenterol. 2025 Jan 8. doi: 10.14309/ajg.0000000000003306.
    PubMed     Abstract available
    
    
    
25. MEMEL Z, Yu A, Fenton C, Wen T, et al
    The Effect of Low-dose Aspirin on Disease Activity in Pregnant Individuals with Inflammatory Bowel Disease.
    Am J Gastroenterol. 2025 Jan 7. doi: 10.14309/ajg.0000000000003304.
    PubMed     Abstract available
    
    
    
26. HONG SJ, Dalal RS, Kuhn KA, Stahly A, et al
    Prevalence and Risk Factors of Spondyloarthritis Symptoms in a US-Based Multicenter Cohort of Patients with Inflammatory Bowel Disease.
    Am J Gastroenterol. 2025 Jan 6. doi: 10.14309/ajg.0000000000003292.
    PubMed     Abstract available
    
    
    
27. GIORDANO A, Perez-Martinez I, Gisbert JP, Ricart E, et al
    Ileal Predominance in Crohn's Disease Is Associated With Increased Intestinal Surgery and Biological Therapy Use, With Lower Treatment Persistence.
    Am J Gastroenterol. 2025;120:194-203.
    PubMed     Abstract available
    
    
    
28. SYAL G, Barnes E, Raffals L, Al Kazzi E, et al
    Medical Therapies for Prevention and Treatment of Inflammatory Pouch Disorders-A Systematic Review and Meta-Analysis.
    Am J Gastroenterol. 2025;120:135-150.
    PubMed     Abstract available
    
    
    December 2024
29. ALLEGRETTI JR, Cheifetz AS, Dulai PS, Stevens AC, et al
    SAFETY, PHARMACOKINETICS, AND CLINICAL EFFICACY OF ADS051, A NEUTROPHIL MODULATOR, IN ULCERATIVE COLITIS: RESULTS OF A RANDOMIZED PHASE 1B TRIAL.
    Am J Gastroenterol. 2024 Dec 31. doi: 10.14309/ajg.0000000000003269.
    PubMed     Abstract available
    
    
    
30. TANDON P, Huang V, Feig DS, Saskin R, et al
    Health-Care Utilization of Children Born to Women with and Without Inflammatory Bowel Disease in the First Five Years of Life: A Population-Cohort Study.
    Am J Gastroenterol. 2024 Dec 31. doi: 10.14309/ajg.0000000000003280.
    PubMed     Abstract available
    
    
    
31. CHETWOOD JD, Paramsothy S, Leong RW
    Infliximab and adalimumab in the treatment of fistulizing Crohn's disease: a propensity score-matched analysis from the prospective Persistence Australian National IBD Cohort (PANIC4) study.
    Am J Gastroenterol. 2024 Dec 30. doi: 10.14309/ajg.0000000000003271.
    PubMed     Abstract available
    
    
    
32. RODRIGUEZ-LAGO I, Aguirre U, Cabriada JL, Ungaro RC, et al
    Increased medication utilization precedes incidentally diagnosed inflammatory bowel disease: a multicenter, case-control study.
    Am J Gastroenterol. 2024 Dec 30. doi: 10.14309/ajg.0000000000003275.
    PubMed     Abstract available
    
    
    
33. GAO Z, Qi J, Ye W
    Comment on "Gallstone Disease Is Associated With an Increased Risk of Inflammatory Bowel Disease: Results From 3 Prospective Cohort Studies".
    Am J Gastroenterol. 2024 Dec 10. doi: 10.14309/ajg.0000000000003186.
    PubMed    
    
    
    November 2024
34. GARCIA MJ, Brenes Y, Vicuna M, Bermejo F, et al
    PERSISTENCE, EFFECTIVENESS, AND SAFETY OF UPADACITINIB IN CROHN'S DISEASE AND ULCERATIVE COLITIS IN REAL LIFE: RESULTS FROM A SPANISH NATIONWIDE STUDY (UREAL STUDY): Upadacitinib for IBD.
    Am J Gastroenterol. 2024 Nov 26. doi: 10.14309/ajg.0000000000003243.
    PubMed     Abstract available
    
    
    
35. SOLITANO V, Narula N, Ma C, Nanayakkara A, et al
    Effectiveness of Ustekinumab for patients with moderate to severe Ulcerative Colitis: A Multi-Center Real-World Canadian Study.
    Am J Gastroenterol. 2024 Nov 14. doi: 10.14309/ajg.0000000000003212.
    PubMed     Abstract available
    
    
    
36. ANDERSON SR, Ayoub M, Coats S, McHenry S, et al
    Safety and Effectiveness of Glucagon-like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease.
    Am J Gastroenterol. 2024 Nov 14. doi: 10.14309/ajg.0000000000003208.
    PubMed     Abstract available
    
    
    
37. TANG WZ, Li JZ, Liu TH
    Tofacitinib vs Biologics: Postoperative Concerns in Ulcerative Colitis Colectomies.
    Am J Gastroenterol. 2024 Nov 14. doi: 10.14309/ajg.0000000000003148.
    PubMed    
    
    
    
38. KAO D, Wong K, Jijon H, Moayyedi P, et al
    Preliminary results from a multicenter, randomized trial using fecal microbial transplantation to induce remission in patients with mild to moderate Crohn's disease.
    Am J Gastroenterol. 2024 Nov 12. doi: 10.14309/ajg.0000000000003196.
    PubMed     Abstract available
    
    
    October 2024
39. ISAACS KL, Sayed CJ
    Nonmalignant dermatologic disorders in Inflammatory Bowel Disease.
    Am J Gastroenterol. 2024 Oct 23. doi: 10.14309/ajg.0000000000003155.
    PubMed     Abstract available
    
    
    
40. DANPANICHKUL P, Duangsonk K, Ho AH, Laoveeravat P, et al
    Disproportionately Increasing Incidence of Inflammatory Bowel Disease in Females and the Elderly: An Update Analysis from the Global Burden of Disease Study 2021.
    Am J Gastroenterol. 2024 Oct 18. doi: 10.14309/ajg.0000000000003143.
    PubMed     Abstract available
    
    
    
41. ADLER J, Galanko JA, Ammoury R, Benkov KJ, et al
    HLA DQA1*05 and risk of anti-TNF treatment failure and anti-drug antibody development in children with Crohn's Disease: HLA DQA1*05 and Pediatric Crohn's Disease.
    Am J Gastroenterol. 2024 Oct 18. doi: 10.14309/ajg.0000000000003135.
    PubMed     Abstract available
    
    
    
42. KHAN N, Patel D, Sundararajan R
    Incidence of thiopurine induced severe myelosuppression in a nationwide cohort of inflammatory bowel disease patients.
    Am J Gastroenterol. 2024 Oct 18. doi: 10.14309/ajg.0000000000003141.
    PubMed     Abstract available
    
    
    
43. CHEN J, Zhai C, Pan H
    Focusing on the Key Factors in the Treatment of Pediatric Crohn's Disease: A Re-Examination of the Relationship Between Body Mass Index and Antitumor Necrosis Factor Treatment Response.
    Am J Gastroenterol. 2024 Oct 10. doi: 10.14309/ajg.0000000000003101.
    PubMed    
    
    
    
44. TEMIDO MJ, Honap S, Bursztejn AC, Portela F, et al
    Drug-Induced Acne in Inflammatory Bowel Disease: A Practical Guide for the Gastroenterologist.
    Am J Gastroenterol. 2024 Oct 9. doi: 10.14309/ajg.0000000000003119.
    PubMed     Abstract available
    
    
    
45. MI N, Yang M, Wei L, Nie P, et al
    Gallstone disease is associated with an increased risk of inflammatory bowel disease: results from three prospective cohort studies.
    Am J Gastroenterol. 2024 Oct 4. doi: 10.14309/ajg.0000000000003111.
    PubMed     Abstract available
    
    
    
46. ABREU MT, Kosinski LR
    Correction to: How Did It Get So Difficult to Care for Patients With Inflammatory Bowel Disease?
    Am J Gastroenterol. 2024 Oct 3. doi: 10.14309/ajg.0000000000003051.
    PubMed    
    
    
    September 2024
47. LIN CP, Kuo P, Wei JC
    Addressing Additional Limitations in the Study on Small Intestine Cancer Risk in Patients With Inflammatory Bowel Disease.
    Am J Gastroenterol. 2024 Sep 27. doi: 10.14309/ajg.0000000000003053.
    PubMed    
    
    
    
48. CHO Y, Choi EY, Choi A, Han JY, et al
    Anti-Tumor Necrosis Factor Therapy and the Risk of Gestational Diabetes in Pregnant Women with Inflammatory Bowel Disease.
    Am J Gastroenterol. 2024 Sep 24. doi: 10.14309/ajg.0000000000003100.
    PubMed     Abstract available
    
    
    
49. FALLOON K, Forney M, Husni ME, Feagan B, et al
    Diagnosis and Management of Inflammatory Bowel Disease Associated Spondyloarthritis.
    Am J Gastroenterol. 2024 Sep 23. doi: 10.14309/ajg.0000000000003092.
    PubMed     Abstract available
    
    
    
50. ISSOKSON K, Lee DY, Yarur AJ, Lewis JD, et al
    The Role of Diet in Inflammatory Bowel Disease Onset, Disease Management, and Surgical Optimization.
    Am J Gastroenterol. 2024 Sep 19. doi: 10.14309/ajg.0000000000003085.
    PubMed     Abstract available
    
    
    
51. VAUGHN BP, Khoruts A, Fischer M
    Diagnosis and management of Clostridioides difficile in inflammatory bowel disease.
    Am J Gastroenterol. 2024 Sep 4. doi: 10.14309/ajg.0000000000003076.
    PubMed     Abstract available
    
    
    
52. YANG JY, Lund JL, Funk MJ, Hudgens MG, et al
    Correction to: Utilization of Treat-to-Target Monitoring Colonoscopy After Treatment Initiation in the US-Based Study of a Prospective Adult Research Cohort With Inflammatory Bowel Disease.
    Am J Gastroenterol. 2024;119:1950.
    PubMed    
    
    
    August 2024
53. KAYAL M, Posner H, Jimenez D, Huang J, et al
    Endoscopic Response Reduces the Risk of Subsequent Pouchitis in Patients with Crohn's Disease Like Pouch Inflammation.
    Am J Gastroenterol. 2024 Aug 27. doi: 10.14309/ajg.0000000000003055.
    PubMed     Abstract available
    
    
    
54. VLADIMIROVA N, Moller J, Attauabi M, Madsen G, et al
    Spine and sacroiliac joint involvement in newly diagnosed inflammatory bowel disease patients - clinical and magnetic resonance imaging findings from a population-based cohort.
    Am J Gastroenterol. 2024 Aug 20. doi: 10.14309/ajg.0000000000003039.
    PubMed     Abstract available
    
    
    
55. NAUDE C, Skvarc D, Maunick B, Evans S, et al
    Acceptance & Commitment Therapy for Adults Living With Inflammatory Bowel Disease & Distress: A Randomized Controlled Trial.
    Am J Gastroenterol. 2024 Aug 20. doi: 10.14309/ajg.0000000000003032.
    PubMed     Abstract available
    
    
    
56. DAI C, Huang YH, Jiang M
    Comparative Risk of Serious Infection With Vedolizumab vs Anti-Tumor Necrosis Factors in Inflammatory Bowel Disease.
    Am J Gastroenterol. 2024 Aug 19. doi: 10.14309/ajg.0000000000002995.
    PubMed    
    
    
    
57. AHMED NS, Krawchuk S, Buhler KA, Solitano V, et al
    US National Estimates of Contemporary Mortality Rates in Patients with Ulcerative Colitis Undergoing Colectomy.
    Am J Gastroenterol. 2024 Aug 14. doi: 10.14309/ajg.0000000000003031.
    PubMed     Abstract available
    
    
    July 2024
58. GLEAVE A, Shah A, Tahir U, Blom JJ, et al
    Using Diet to Treat Inflammatory Bowel Disease: A Systematic Review.
    Am J Gastroenterol. 2024 Jul 26. doi: 10.14309/ajg.0000000000002973.
    PubMed     Abstract available
    
    
    
59. LEE JW, Woo D, Kim KO, Kim ES, et al
    Deep learning model using stool pictures for predicting endoscopic mucosal inflammation in patients with ulcerative colitis.
    Am J Gastroenterol. 2024 Jul 25. doi: 10.14309/ajg.0000000000002978.
    PubMed     Abstract available
    
    
    
60. ALSAKARNEH S, Ahmed M, Azim S, Hashash JG, et al
    Risk of Small Intestine Cancer in Inflammatory Bowel Disease: A Propensity-Matched Study from a Large Multi-Center Database in the United States.
    Am J Gastroenterol. 2024 Jul 25. doi: 10.14309/ajg.0000000000002984.
    PubMed     Abstract available
    
    
    
61. PINNUCK B, Lynch KD
    Mortality in Acute Severe Ulcerative Colitis - Still an Alarming and Real Complication in the Era of Advanced Therapies.
    Am J Gastroenterol. 2024 Jul 16. doi: 10.14309/ajg.0000000000002917.
    PubMed    
    
    
    
62. CALAFAT M, Suria C, Mesonero F, de Francisco R, et al
    HIV infection is associated with a less aggressive phenotype of inflammatory bowel disease. A multicenter study of the ENEIDA registry.
    Am J Gastroenterol. 2024 Jul 15. doi: 10.14309/ajg.0000000000002965.
    PubMed     Abstract available
    
    
    
63. SHAH RS, Hu JH, Bachour S, Joseph A, et al
    Histologic Activity from Neoterminal Ileal Biopsies in Patients with Crohn's Disease in Endoscopic Remission is Associated with Postoperative Recurrence.
    Am J Gastroenterol. 2024 Jul 15. doi: 10.14309/ajg.0000000000002963.
    PubMed     Abstract available
    
    
    
64. KARLQVIST S, Sachs MC, Eriksson C, Cao Y, et al
    Comparative risk of serious infection with vedolizumab vs anti-TNF in inflammatory bowel disease: results from nationwide Swedish registers.
    Am J Gastroenterol. 2024 Jul 12. doi: 10.14309/ajg.0000000000002961.
    PubMed     Abstract available
    
    
    
65. KOCHHAR GS, Khataniar H, Jairath V, Farraye FA, et al
    Comparative Effectiveness of Upadacitinib and Tofacitinib in Ulcerative Colitis: A U.S. Propensity-Matched Cohort Study.
    Am J Gastroenterol. 2024 Jul 5. doi: 10.14309/ajg.0000000000002947.
    PubMed     Abstract available
    
    
    
66. DEJONG N, Zhang X, Kappelman M
    Prevalence of Preceding and Follow-up Outpatient Care Surrounding Emergency Department Visits for Pediatric Inflammatory Bowel Disease: Identifying Opportunities for Quality Improvement.
    Am J Gastroenterol. 2024 Jul 5. doi: 10.14309/ajg.0000000000002936.
    PubMed     Abstract available
    
    
    
67. TANDON P, Huang V, Feig DS, Saskin R, et al
    Recent Immigrants With Inflammatory Bowel Disease Have Significant Healthcare Utilization From Preconception to Postpartum: A Population Cohort Study.
    Am J Gastroenterol. 2024;119:1346-1354.
    PubMed     Abstract available
    
    
    June 2024
68. MURTHY SK, Tandon P, Matthews P, Ahmed F, et al
    A Population-Based Matched Cohort Study of Digestive System Cancer Incidence and Mortality in Individuals With and Without Inflammatory Bowel Disease.
    Am J Gastroenterol. 2024 Jun 25. doi: 10.14309/ajg.0000000000002900.
    PubMed     Abstract available
    
    
    
69. BARNES EL, Desai A, Hashash JG, Farraye FA, et al
    The Natural History after Ileal Pouch-Anal Anastomosis for Ulcerative Colitis: A Population-Based Cohort Study from the United States.
    Am J Gastroenterol. 2024 Jun 18. doi: 10.14309/ajg.0000000000002891.
    PubMed     Abstract available
    
    
    
70. KATHURIA P, Higgins PDR, Berinstein JA
    Timing Is Everything: The Lifesaving Potential of Early Medical Therapy in Acute Severe Ulcerative Colitis.
    Am J Gastroenterol. 2024 Jun 12. doi: 10.14309/ajg.0000000000002867.
    PubMed    
    
    
    
71. CONSTANT BD, Long MD, Scott FI, Higgins PDR, et al
    Associated With Decreased Insurance Satisfaction and Adverse Clinical Outcomes: An Inflammatory Bowel Disease Partners Survey.
    Am J Gastroenterol. 2024 Jun 3. doi: 10.14309/ajg.0000000000002851.
    PubMed     Abstract available
    
    
    May 2024
72. NOURELDIN M, Van T, Cohen-Mekelburg S, Scott FI, et al
    Legalization of Cannabis Does Not Reduce Opioid Prescribing in Patients With Inflammatory Bowel Disease: A Difference-in-Difference Analysis.
    Am J Gastroenterol. 2024 May 21. doi: 10.14309/ajg.0000000000002834.
    PubMed     Abstract available
    
    
    
73. KARIME C, Black CN, Cortes P, Kwon JY, et al
    Utility of a Third Heplisav-B Dose in Patients with Inflammatory Bowel Disease without Immunity Following Two-Dose Heplisav-B Vaccination.
    Am J Gastroenterol. 2024 May 8. doi: 10.14309/ajg.0000000000002863.
    PubMed     Abstract available
    
    
    
74. NARULA N, Hamam H, Peerani F, Bessissow T, et al
    Resolution of rectal bleeding by day 7 in acute severe ulcerative colitis is prognostic for post-discharge corticosteroid free clinical remission and endoscopic improvement.
    Am J Gastroenterol. 2024 May 8. doi: 10.14309/ajg.0000000000002860.
    PubMed     Abstract available
    
    
    
75. WU S, Liu Y, He Z, Bai Y, et al
    The Association Between Ultra-Processed Foods and Inflammatory Bowel Disease: Far More Complex Than Thought.
    Am J Gastroenterol. 2024 May 3. doi: 10.14309/ajg.0000000000002815.
    PubMed    
    
    
    
76. BERNSTEIN CN, Fisk JD, Dolovich C, Hitchon CA, et al
    Understanding Predictors of Fatigue Over Time in Persons With Inflammatory Bowel Disease: The Importance of Depressive and Anxiety Symptoms.
    Am J Gastroenterol. 2024;119:922-929.
    PubMed     Abstract available
    
    
    April 2024
77. ABREU MT, Kosinski LR
    How Did It Get So Difficult to Care for Patients With Inflammatory Bowel Disease?
    Am J Gastroenterol. 2024 Apr 30. doi: 10.14309/ajg.0000000000002794.
    PubMed    
    
    
    
78. STIDHAM RW, Enchakalody B, Wang SC, Su GL, et al
    Artificial Intelligence for Quantifying Cumulative Small Bowel Disease Severity on CT-Enterography in Crohn's Disease.
    Am J Gastroenterol. 2024 Apr 25. doi: 10.14309/ajg.0000000000002828.
    PubMed     Abstract available
    
    
    
79. MOHAMED MFH, Marino D, Elfert K, Beran A, et al
    Dye Chromoendoscopy Outperforms High-Definition White Light Endoscopy in Dysplasia Detection for Patients With Inflammatory Bowel Disease: An Updated Meta-Analysis of Randomized Controlled Trials.
    Am J Gastroenterol. 2024;119:719-726.
    PubMed     Abstract available
    
    
    March 2024
80. ALLEGRETTI JR, Axelrad J, Dalal RS, Kelly CR, et al
    Outcomes after Fecal Microbiota Transplantation in combination with Bezlotoxumab for Inflammatory Bowel Disease and Recurrent C . difficile Infection.
    Am J Gastroenterol. 2024 Mar 19. doi: 10.14309/ajg.0000000000002770.
    PubMed     Abstract available
    
    
    
81. KHAN N, Sundararajan R, Patel M, Trivedi C, et al
    Effectiveness Of Tofacitinib In Ulcerative Colitis Patients: A Nationwide Veterans Administration Cohort study.
    Am J Gastroenterol. 2024 Mar 14. doi: 10.14309/ajg.0000000000002761.
    PubMed     Abstract available
    
    
    
82. DALAL RS, Kallumkal G, Cabral HJ, Barnes EL, et al
    One-Year Comparative Effectiveness of Upadacitinib Versus Tofacitinib For Ulcerative Colitis: A Multicenter Cohort Study.
    Am J Gastroenterol. 2024 Mar 12. doi: 10.14309/ajg.0000000000002746.
    PubMed     Abstract available
    
    
    
83. EBACH DR, Jester TW, Galanko JA, Firestine AM, et al
    High Body Mass Index and Response to Anti-TNF Therapy in Pediatric Crohn Disease.
    Am J Gastroenterol. 2024 Mar 6. doi: 10.14309/ajg.0000000000002741.
    PubMed     Abstract available
    
    
    
84. CHUGH R, Long MD, Jiang Y, Weaver KN, et al
    Maternal and Neonatal Outcomes in Vedolizumab- and Ustekinumab-Exposed Pregnancies: Results From the PIANO Registry.
    Am J Gastroenterol. 2024;119:468-476.
    PubMed     Abstract available
    
    
    February 2024
85. ANDERSON KL, Anand R, Feuerstein JD
    Insurance Companies' Poor Adherence to Guidelines for Moderate to Severe Ulcerative Colitis/Crohn's Disease Management.
    Am J Gastroenterol. 2024 Feb 29. doi: 10.14309/ajg.0000000000002720.
    PubMed     Abstract available
    
    
    
86. FRIEDMAN S, Nielsen J, Qvist N, Knudsen T, et al
    Does surgery prior to pregnancy in women with inflammatory bowel disease increase the risk of adverse maternal and fetal outcomes? A Danish national cohort study.
    Am J Gastroenterol. 2024 Feb 20. doi: 10.14309/ajg.0000000000002732.
    PubMed     Abstract available
    
    
    
87. HERFARTH H
    Dysplasia Detection in Inflammatory Bowel Disease: An Updated Meta-Analysis With Effect.
    Am J Gastroenterol. 2024 Feb 16. doi: 10.14309/ajg.0000000000002658.
    PubMed    
    
    
    
88. SMITH RA, Desai A, Barnes EL, Hayney M, et al
    Patients with Inflammatory Bowel Disease are at Increased Risk for Hospitalization Due to Respiratory Syncytial Virus.
    Am J Gastroenterol. 2024 Feb 6. doi: 10.14309/ajg.0000000000002682.
    PubMed     Abstract available
    
    
    
89. SUN J, Yao J, Olen O, Halfvarson J, et al
    Long-term risk of myocarditis in patients with inflammatory bowel disease: a nationwide cohort study in Sweden.
    Am J Gastroenterol. 2024 Feb 5. doi: 10.14309/ajg.0000000000002701.
    PubMed     Abstract available
    
    
    
90. COHEN-MEKELBURG S, Valicevic A, Lin L, Saini SD, et al
    Inflammatory Bowel Disease Hospitalizations are Similar for Patients Receiving Tele-Visit Delivered Outpatient Care and Those Receiving Traditional In-Person Care.
    Am J Gastroenterol. 2024 Feb 5. doi: 10.14309/ajg.0000000000002703.
    PubMed     Abstract available
    
    
    
91. VAGIANOS K, Dolovich C, Witges K, Graff LA, et al
    Ultra-processed food, disease activity and inflammation in Ulcerative Colitis: The Manitoba Living with IBD Study.
    Am J Gastroenterol. 2024 Feb 2. doi: 10.14309/ajg.0000000000002667.
    PubMed     Abstract available
    
    
    
92. DRAGONI G, Innocenti T, Amiot A, Castiglione F, et al
    Rates of adverse events in patients with ulcerative colitis undergoing colectomy during treatment with tofacitinib vs biologics: a multicenter observational study.
    Am J Gastroenterol. 2024 Feb 2. doi: 10.14309/ajg.0000000000002676.
    PubMed     Abstract available
    
    
    
93. ANDREW B, Trinh S, Zhou A, Vasudevan A, et al
    Anal Cancer in Crohn's Disease: The Need to Optimize Treatment and Improve Surveillance.
    Am J Gastroenterol. 2024;119:390-391.
    PubMed    
    
    
    
94. COWARD S, Benchimol EI, Bernstein CN, Avina-Zubieta A, et al
    Forecasting the Incidence and Prevalence of Inflammatory Bowel Disease: A Canadian nationwide analysis.
    Am J Gastroenterol. 2024 Feb 1. doi: 10.14309/ajg.0000000000002687.
    PubMed     Abstract available
    
    
    
95. FAYE AS, Axelrad JE, Sun J, Halfvarson J, et al
    Atherosclerosis as a Risk Factor of Inflammatory Bowel Disease: A Population-Based Case-Control Study.
    Am J Gastroenterol. 2024;119:313-322.
    PubMed     Abstract available
    
    
    
96. DALAL RS, Norgard BM, Zegers FD, Kjeldsen J, et al
    Older Adult-Onset of Inflammatory Bowel Diseases Is Associated With Higher Utilization of Analgesics: A Nationwide Cohort Study.
    Am J Gastroenterol. 2024;119:323-330.
    PubMed     Abstract available
    
    
    
97. FEAGINS LA, Gold S, Steinlauf AF
    Overview of Biosimilars in Inflammatory Bowel Diseases.
    Am J Gastroenterol. 2024;119:229-232.
    PubMed    
    
    
    January 2024
98. CHETWOOD JD, Ko Y, Pudipeddi A, Kariyawasam V, et al
    Biological agents in the treatment of Crohn's disease: a propensity score-matched analysis from the prospective Persistence Australian National IBD Cohort (PANIC3) study.
    Am J Gastroenterol. 2024 Jan 26. doi: 10.14309/ajg.0000000000002679.
    PubMed     Abstract available
    
    
    
99. BERINSTEIN JA, Karl T, Patel A, Dolinger M, et al
    Effectiveness of Upadacitinib for Patients with Acute Severe Ulcerative Colitis: A Multi-Center Experience.
    Am J Gastroenterol. 2024 Jan 26. doi: 10.14309/ajg.0000000000002674.
    PubMed     Abstract available
    
    
    
100. TANDON P, Huang V, Feig DS, Saskin R, et al
     Recent Immigrants with Inflammatory Bowel Disease Have Significant Health-Care Utilization from Preconception to Postpartum: A Population Cohort Study.
     Am J Gastroenterol. 2024 Jan 23. doi: 10.14309/ajg.0000000000002668.
     PubMed     Abstract available
     
     
     
101. NARULA N, Wong ECL, Dulai PS, Marshall JK, et al
     Delayed Ustekinumab and Adalimumab Responders Have Similar Outcomes as Early Responders in Biologic-Naive Crohn's Disease.
     Am J Gastroenterol. 2024 Jan 18. doi: 10.14309/ajg.0000000000002654.
     PubMed     Abstract available
     
     
     
102. MA T, Han D, Sun M
     Acute Pancreatitis After Microscopic Colitis: Is It due to Drugs or Disease?
     Am J Gastroenterol. 2024;119:215-216.
     PubMed    
     
     
     
103. KIWAN W
     Continuing Medical Education Questions: January 2024.
     Am J Gastroenterol. 2024;119:29.
     PubMed     Abstract available
     
     
     December 2023
104. DOLINGER MT, Aronskyy I, Kellar A, Gao M, et al
     Determining the accuracy of intestinal ultrasound scores as a pre-screening tool in Crohn's disease clinical trials.
     Am J Gastroenterol. 2023 Dec 22. doi: 10.14309/ajg.0000000000002632.
     PubMed     Abstract available
     
     
     
105. SINGH A, Goyal MK, Midha V, Mahajan R, et al
     Tofacitinib in acute severe ulcerative colitis (TACOS): A randomized controlled trial: Tofacitinib in ASUC.
     Am J Gastroenterol. 2023 Dec 22. doi: 10.14309/ajg.0000000000002635.
     PubMed     Abstract available
     
     
     
106. AFIF W, Arasaradnam RP, Abreu MT, Danese S, et al
     Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-term Maintenance Study.
     Am J Gastroenterol. 2023 Dec 14. doi: 10.14309/ajg.0000000000002621.
     PubMed     Abstract available
     
     
     
107. WEI L, Patil SA, Cross RK, Taubenslag KJ, et al
     Cystoid macular edema after initiation of ozanimod for ulcerative colitis.
     Am J Gastroenterol. 2023 Dec 12. doi: 10.14309/ajg.0000000000002622.
     PubMed    
     
     
     
108. BOUSVAROS A
     Collaborative Registries for Pediatric Crohn's Disease: A Leap Forward or More of the Same?
     Am J Gastroenterol. 2023 Dec 5. doi: 10.14309/ajg.0000000000002590.
     PubMed    
     
     
     
109. WEISS A, Barnes EL, Bewtra M
     A Practical Guide to the Use of Upadacitinib in Ulcerative Colitis and Crohn's Disease.
     Am J Gastroenterol. 2023 Dec 4. doi: 10.14309/ajg.0000000000002598.
     PubMed    
     
     
     
110. BOURGONJE AR, Mian P
     Identifying Phenotypic Determinants of Infliximab Target Concentrations in Inflammatory Bowel Disease: Toward Personalized Evidence-Based Dosing Regimens.
     Am J Gastroenterol. 2023;118:2308-2309.
     PubMed    
     
     
     
111. DULANEY DT
     Continuing Medical Education Questions: December 2023.
     Am J Gastroenterol. 2023;118:2122.
     PubMed     Abstract available
     
     
     November 2023
112. KAYAL M, Deepak P, Beniwal-Patel P, Raffals L, et al
     Changes in Therapy Are Not Associated with Increased Remission in Patients with Crohn's Disease of the Pouch.
     Am J Gastroenterol. 2023 Nov 17. doi: 10.14309/ajg.0000000000002599.
     PubMed     Abstract available
     
     
     
113. ANDREW B, Vasudevan A, Srinivasan A
     The Role of Intestinal Ultrasound During Pregnancy in Patients With Inflammatory Bowel Disease.
     Am J Gastroenterol. 2023;118:2096-2097.
     PubMed    
     
     
     
114. BARNES EL, Desai A, Kochhar GS
     The Comparative Effectiveness of Ciprofloxacin and Metronidazole for an Initial Episode of Pouchitis: A Propensity-Matched Study.
     Am J Gastroenterol. 2023;118:1989-1996.
     PubMed     Abstract available
     
     
     
115. SANTIAGO P, Barnes EL, Raffals LE
     Classification and Management of Disorders of the J Pouch.
     Am J Gastroenterol. 2023;118:1931-1939.
     PubMed     Abstract available
     
     
     
116. SACHDEVA K, Agarwal S, Kumar P, Mathew D, et al
     Revised Algorithmic Approach to Differentiate Between Nonspecific and Specific Etiologies of Chronic Terminal Ileitis.
     Am J Gastroenterol. 2023;118:2052-2060.
     PubMed     Abstract available
     
     
     
117. YARUR AJ, Abreu MT, Deepak P, Beniwal-Patel P, et al
     Patients With Inflammatory Bowel Diseases and Higher Visceral Adipose Tissue Burden May Benefit From Higher Infliximab Concentrations to Achieve Remission.
     Am J Gastroenterol. 2023;118:2005-2013.
     PubMed     Abstract available
     
     
     
118. MOHAN BP, Fatima N, Khan SR, Kassab L, et al
     Early Remission With Induction Therapy Predicts Long-Term Remission in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
     Am J Gastroenterol. 2023;118:2084-2087.
     PubMed    
     
     
     
119. KOCHAR B, Mao EJ, Shah SA
     Optimal Dysplasia Detection and Management in IBD: Now and in the Future.
     Am J Gastroenterol. 2023;118:1905-1908.
     PubMed    
     
     
     
120. DUNLEAVY KA, Cross RK, Raffals LE
     Causes, Diagnostic Testing, and Treatment of Residual Symptoms in Patients With IBD With Quiescent Disease.
     Am J Gastroenterol. 2023;118:1909-1914.
     PubMed    
     
     
     October 2023
121. GENERE JR, Ballard DH, Deepak P
     Three-Dimensional Modeling to Guide Interventional Endoscopy in Fibrostenotic Crohn's Disease.
     Am J Gastroenterol. 2023 Oct 13. doi: 10.14309/ajg.0000000000002558.
     PubMed    
     
     
     
122. PHAM JT, Ghusn W, Acosta A, Loftus EV Jr, et al
     Effectiveness and Safety of Antiobesity Medications in Patients With Obesity and Inflammatory Bowel Disease.
     Am J Gastroenterol. 2023 Oct 9. doi: 10.14309/ajg.0000000000002490.
     PubMed     Abstract available
     
     
     
123. DEBRUYN JC, Huynh HQ, Griffiths AM, Jacobson K, et al
     ADALIMUMAB VERSUS INFLIXIMAB IN LUMINAL PEDIATRIC CROHN'S DISEASE: COMPARABLE OUTCOMES IN A PROSPECTIVE MULTICENTER COHORT STUDY.
     Am J Gastroenterol. 2023 Oct 3. doi: 10.14309/ajg.0000000000002552.
     PubMed     Abstract available
     
     
     
124. SHUJA A
     Continuing Medical Education Questions: October 2023.
     Am J Gastroenterol. 2023;118:1742.
     PubMed     Abstract available
     
     
     
125. COELHO-PRABHU N, Lewis JD
     Update on Endoscopic Dysplasia Surveillance in Inflammatory Bowel Disease.
     Am J Gastroenterol. 2023;118:1748-1755.
     PubMed     Abstract available
     
     
     September 2023
126. ALSOUD D, Ho J, Sabino J, Ferrante M, et al
     Utility of the Serum-Based Endoscopic Healing Index in Monitoring Therapeutic Response in Ulcerative Colitis.
     Am J Gastroenterol. 2023 Sep 27. doi: 10.14309/ajg.0000000000002518.
     PubMed     Abstract available
     
     
     
127. BAK MTJ, Huinink STB, Erler NS, Bodelier AGL, et al
     Prognostic value of the modified Rutgeerts' score for long-term outcomes after primary ileocecal resection in Crohn's disease.
     Am J Gastroenterol. 2023 Sep 22. doi: 10.14309/ajg.0000000000002509.
     PubMed     Abstract available
     
     
     
128. CAIRNS CA, Cross RK, Khambaty M, Bafford AC, et al
     Monitoring Patients with Inflammatory Bowel Disease at High Risk of Anal Cancer.
     Am J Gastroenterol. 2023 Sep 18. doi: 10.14309/ajg.0000000000002503.
     PubMed     Abstract available
     
     
     
129. SANTIAGO P, Coelho-Prabhu N, Lennon R, Rui S, et al
     Baseline Clinical Factors are Associated with Risk of Complications in Crohn's Disease: Appraisal of the AGA Clinical Care Pathway.
     Am J Gastroenterol. 2023 Sep 15. doi: 10.14309/ajg.0000000000002498.
     PubMed     Abstract available
     
     
     
130. WILKERSON RC
     Continuing Medical Education Questions: September 2023.
     Am J Gastroenterol. 2023;118:1543.
     PubMed     Abstract available
     
     
     
131. KAHN-BOESEL O, Cautha S, Ufere NN, Ananthakrishnan AN, et al
     A Narrative Review of Financial Burden, Distress, and Toxicity of Inflammatory Bowel Diseases in the United States.
     Am J Gastroenterol. 2023;118:1545-1553.
     PubMed     Abstract available
     
     
     August 2023
132. CHANG S, Murphy M, Malter L
     A Review of Available Medical Therapies to Treat Moderate to Severe Inflammatory Bowel Disease in 2023.
     Am J Gastroenterol. 2023 Aug 24. doi: 10.14309/ajg.0000000000002485.
     PubMed     Abstract available
     
     
     
133. LEVARTOVSKY A, Ben-Horin S, Kopylov U, Klang E, et al
     Towards AI-Augmented Clinical Decision Making: An Examination of ChatGPT's Utility in Acute Ulcerative Colitis Presentations.
     Am J Gastroenterol. 2023 Aug 23. doi: 10.14309/ajg.0000000000002483.
     PubMed     Abstract available
     
     
     
134. YANG Y, Ludvigsson JF, Olen O, Sjolander A, et al
     Absolute and relative risks of kidney and urological complications in patients with inflammatory bowel disease.
     Am J Gastroenterol. 2023 Aug 10. doi: 10.14309/ajg.0000000000002473.
     PubMed     Abstract available
     
     
     
135. RAMPERTAB SD
     Continuing Medical Education Questions: August 2023.
     Am J Gastroenterol. 2023;118:1321.
     PubMed     Abstract available
     
     
     
136. BOPARAI ES, Lee JK, Zhu S, Shirazi A, et al
     The Contemporary Probability of Occult Colorectal Cancer in Patients With Colitis-Related Dysplasia Undergoing Colectomy.
     Am J Gastroenterol. 2023;118:1453-1456.
     PubMed     Abstract available
     
     
     July 2023
137. DUBINSKY M, Bleakman AP, Panaccione R, Hibi T, et al
     Bowel Urgency in Ulcerative Colitis: Current Perspectives and Future Directions.
     Am J Gastroenterol. 2023 Jul 12. doi: 10.14309/ajg.0000000000002404.
     PubMed     Abstract available
     
     
     
138. FERNANDEZ C, Gajic Z, Esen E, Remzi F, et al
     Preoperative Risk Factors for Adverse Events in Adults Undergoing Bowel Resection for Inflammatory Bowel Disease: 15-Year Assessment of ACS-NSQIP.
     Am J Gastroenterol. 2023 Jul 7. doi: 10.14309/ajg.0000000000002395.
     PubMed     Abstract available
     
     
     
139. BONFILS L, Sandri AK, Poulsen GJ, Agrawal M, et al
     Medication-wide study: Exploring medication use ten years prior to a diagnosis of inflammatory bowel disease.
     Am J Gastroenterol. 2023 Jul 7. doi: 10.14309/ajg.0000000000002399.
     PubMed     Abstract available
     
     
     
140. BACHOUR SP, Khan MZ, Shah RS, Joseph A, et al
     Anastomotic configuration and temporary diverting ileostomy do not increase risk for anastomotic stricture in postoperative Crohn's disease.
     Am J Gastroenterol. 2023 Jul 7. doi: 10.14309/ajg.0000000000002393.
     PubMed     Abstract available
     
     
     
141. VUYYURU SK, Archer M, Nguyen TM, Beaton M, et al
     Long washout periods between biologics for inflammatory bowel disease clinical trials are unnecessary: A Canadian retrospective cohort study.
     Am J Gastroenterol. 2023 Jul 6. doi: 10.14309/ajg.0000000000002398.
     PubMed     Abstract available
     
     
     
142. BALI AS, Hashash JG, Picco MF, Kinnucan JA, et al
     Electronic Health Record Burden Among Gastroenterology Providers Associated With Subspecialty and Training.
     Am J Gastroenterol. 2023;118:1282-1284.
     PubMed     Abstract available
     
     
     June 2023
143. HU FH, Chen HL
     Low Risk of Lymphoma in Pediatric Patients Treated for Inflammatory Bowel Disease: Need More Evidence.
     Am J Gastroenterol. 2023;118:1101-1102.
     PubMed    
     
     
     
144. DULANEY DT
     Continuing Medical Education Questions: June 2023.
     Am J Gastroenterol. 2023;118:935.
     PubMed     Abstract available
     
     
     
145. DULANEY DT
     Continuing Medical Education Questions: June 2023.
     Am J Gastroenterol. 2023;118:935.
     PubMed     Abstract available
     
     
     May 2023
146. MARKOVINOVIC A, Quan J, Herauf M, Hracs L, et al
     Adverse Events & Serological Responses Following SARS-CoV-2 Vaccination in Individuals with Inflammatory Bowel Disease.
     Am J Gastroenterol. 2023 May 22. doi: 10.14309/ajg.0000000000002337.
     PubMed     Abstract available
     
     
     
147. BARNES EL, Zhang X, Long MD, Herfarth HH, et al
     Rate of Colectomy Increases within Twelve Months of Sequential Therapy for Ulcerative Colitis.
     Am J Gastroenterol. 2023 May 22. doi: 10.14309/ajg.0000000000002331.
     PubMed     Abstract available
     
     
     
148. PARIAN AM, Obi M, Fleshner P, Schwartz DA, et al
     Management of Perianal Crohn's Disease - AJG.
     Am J Gastroenterol. 2023 May 19. doi: 10.14309/ajg.0000000000002326.
     PubMed     Abstract available
     
     
     
149. LEY D, Leroyer A, Dupont C, Sarter H, et al
     New therapeutic strategies are associated with a significant decrease in colectomy rate in pediatric ulcerative colitis.
     Am J Gastroenterol. 2023 May 4. doi: 10.14309/ajg.0000000000002316.
     PubMed     Abstract available
     
     
     
150. GOLDOWSKY A, Billings W, Kickel A, Charabaty A, et al
     @MondayNightIBD and the Expanding Gastroenterology Twitterverse: A Study on Continuing Medical Education on #GITwitter.
     Am J Gastroenterol. 2023;118:855-860.
     PubMed     Abstract available
     
     
     April 2023
151. MORTREUX P, Leroyer A, Dupont C, Ley D, et al
     Natural history of anal ulcerations in pediatric-onset Crohn's disease: long-term follow-up of a population-based study.
     Am J Gastroenterol. 2023 Apr 25. doi: 10.14309/ajg.0000000000002301.
     PubMed     Abstract available
     
     
     
152. COHEN-MEKELBURG S, Van T, Berinstein JA, Yu X, et al
     Characteristics of Facilities with Early and Rapid Ustekinumab Adoption for Patients with Inflammatory Bowel Disease.
     Am J Gastroenterol. 2023 Apr 25. doi: 10.14309/ajg.0000000000002304.
     PubMed     Abstract available
     
     
     
153. YANG JY, Lund JL, Funk MJ, Hudgens MG, et al
     Utilization of Treat-to-Target Monitoring Colonoscopy after Treatment Initiation in the US-Based Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease (SPARC IBD).
     Am J Gastroenterol. 2023 Apr 13. doi: 10.14309/ajg.0000000000002294.
     PubMed     Abstract available
     
     
     
154. MARCHEGIANI F, Laurent A, de'Angelis N
     Abdominal mass in a patient with autoimmune hepatitis, ulcerative colitis and BRCA family history - not always what you expect.
     Am J Gastroenterol. 2023 Apr 11. doi: 10.14309/ajg.0000000000002284.
     PubMed    
     
     
     March 2023
155. AHUJA D, Murad MH, Ma C, Jairath V, et al
     Comparative Speed of Early Symptomatic Remission with Advanced Therapies for Moderate-Severe Ulcerative Colitis: A Systematic Review and Network Meta-Analysis.
     Am J Gastroenterol. 2023 Mar 29. doi: 10.14309/ajg.0000000000002263.
     PubMed     Abstract available
     
     
     
156. OGINO T, Mizushima T, Fujii M, Sekido Y, et al
     Crohn's disease-associated anorectal cancer has a poor prognosis with high local recurrence: a subanalysis of the Nationwide Japanese Study.
     Am J Gastroenterol. 2023 Mar 28. doi: 10.14309/ajg.0000000000002269.
     PubMed     Abstract available
     
     
     
157. ZORZI F, Rubin DT, Cleveland NK, Monteleone G, et al
     Ultrasonographic Transmural healing in Crohn's disease.
     Am J Gastroenterol. 2023 Mar 28. doi: 10.14309/ajg.0000000000002265.
     PubMed     Abstract available
     
     
     
158. FINE LS, Zhu S, Shirazi A, Lee JK, et al
     Increased Risk of Hospitalization, Surgery and Venous Thromboembolism Among Patients with Inflammatory Bowel Disease and Malnutrition in a Large, Community-Based Healthcare System.
     Am J Gastroenterol. 2023 Mar 9. doi: 10.14309/ajg.0000000000002241.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.